Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

William Knox

Anesthesiology Rolla, MO Doctor of Osteopathy

NPI 1205989084 CMS profile 145305

1000 W 10Th St, Rolla, MO 65401

Open in the dashboard

General payments

$3,598

90 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, William Knox of Rolla, MO is reported in the CMS Open Payments database as having received $3,598 across 90 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Anesthesiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $777 21
2024 General $253 16
2023 General $263 14
2022 General $183 9
2021 General $146 7
2020 General $96 3
2019 General $1,882 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Knox
  • Anesthesiology median
  • Middle half of Anesthesiology
  • National median

In program year 2025, general payments to William Knox were reported at $777. Among 18,548 Anesthesiology profiles paid that year, the median was $58 and the middle half received between $26 and $153.

Show as a table
Year William Knox Anesthesiology median Middle half National median
2019 $1,882 $72 $23–$151 $163
2020 $96 $36 $17–$120 $114
2021 $146 $49 $21–$135 $132
2022 $183 $52 $22–$144 $149
2023 $263 $53 $23–$143 $160
2024 $253 $55 $25–$150 $164
2025 $777 $58 $26–$153 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic USA, Inc. $1,558 11 payments
  2. Foundation Fusion Solutions, LLC $548 15 payments
  3. Nevro Corp. $409 18 payments
  4. Medtronic, Inc. $292 20 payments
  5. BIOTRONIK NRO, Inc. $126 4 payments
  6. Stryker Corporation $110 2 payments
  7. Stimwave Technologies Incorporated $109 1 payment
  8. Abbott Laboratories $84 1 payment
  9. Electronic Waveform Lab, Inc. $76 2 payments
  10. AbbVie, Inc. $70 3 payments
  11. Other $216 13 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,555 88 payments
  2. Travel and Lodging $1,044 2 payments
Products named General payments · program years 2019–2025
  1. SYNCHROMED $1,482 8 payments
  2. Omnia $264 10 payments
  3. Senza $145 8 payments
  4. INTELLIS ADAPTIVESTIM $128 10 payments
  5. SPINEJACK $110 2 payments
  6. Prospera $104 3 payments
  7. ETERNA $84 1 payment
  8. RESTORE $76 3 payments
  9. KYPHON EXPRESS II KYPHOPAK TRAY $74 4 payments
  10. UBRELVY $46 2 payments
  11. Other $509 30 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

1,307

Median for Critical Care (Intensivists): 406

Drug cost

$47,345

Median for Critical Care (Intensivists): $197,260

Branded share of claims

66.6%

Median for Critical Care (Intensivists): 69%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hysingla Er Hydrocodone Bitartrate Brand 23 $11,127
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 385 $9,610
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 295 $9,388
Pregabalin Generic 85 $4,151
Xtampza Er Oxycodone Myristate Brand 11 $3,784
Morphine Sulfate Er Morphine Sulfate Brand 100 $2,264
Tramadol Hcl Er Tramadol Hcl Brand 39 $1,962
Fentanyl Generic 11 $1,682
Oxycodone Hcl Generic 78 $1,416
Tramadol Hcl Generic 86 $859

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,531 Part D prescribers listed as Critical Care (Intensivists); they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$19,128

Medicare's payments for the services billed

Medicare patients

85

Average age 70

Services billed

256

53 women, 32 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 40%
Diabetes 39%
Ischemic heart disease 33%
COPD 33%
Heart failure 22%
Chronic kidney disease 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

90 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Anesthesiology in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record